about
Empirical management of community-acquired pneumonia: impact of concurrent A/H1N1 influenza pandemic on guideline implementation.Factors Influencing the Use of a Mobile App for Reporting Adverse Drug Reactions and Receiving Safety Information: A Qualitative Study.The influence that electronic prescribing has on medication errors and preventable adverse drug events: an interrupted time-series study.Impact of adverse drug events and treatment satisfaction on patient adherence with antihypertensive medication - a study in ambulatory patients.Understanding drug preferences, different perspectives.Reliability of assessment of adherence to an antimicrobial treatment guideline.Comparison of methods for identifying patients at risk of medication-related harm.Comparison of potential risk factors for medication errors with and without patient harm.Preventable and non-preventable adverse drug events in hospitalized patients: a prospective chart review in the Netherlands.Impact of safety-related regulatory action on clinical practice: a systematic review.Additional safety risk to exceptionally approved drugs in Europe?Improving clinical trials for cardiovascular diseases: a position paper from the Cardiovascular Round Table of the European Society of Cardiology.Surrogate endpoints in clinical trials of chronic kidney disease progression: moving from single to multiple risk marker response scores.Benefit-Risk Assessment, Communication, and Evaluation (BRACE) throughout the life cycle of therapeutic products: overall perspective and role of the pharmacoepidemiologist.Communication on Safety of Medicines in Europe: Current Practices and General Practitioners' Awareness and Preferences.Adverse drug reaction reports for cardiometabolic drugs from sub-Saharan Africa: a study in VigiBase.A decade of safety-related regulatory action in the Netherlands: a retrospective analysis of direct healthcare professional communications from 1999 to 2009.Hypertension treatment practices and its determinants among ambulatory patients: retrospective cohort study in Ethiopia.Limited effect of patient and disease characteristics on compliance with hospital antimicrobial guidelines.Adherence barriers to antimicrobial treatment guidelines in teaching hospital, the Netherlands.Use of antibacterial fixed-dose combinations in the private sector in eight Latin American Countries between 1999 and 2009.Cost-effectiveness of an electronic medication ordering system (CPOE/CDSS) in hospitalized patients.Post-approval safety issues with innovative drugs: a European cohort study.Influence of renal dysfunction on the pharmacokinetics of the selective Na+/H+ exchange inhibitor EMD 87 580 in patients with chronic heart failure.Registries supporting new drug applications.Is Chronic Dialysis the Right Hard Renal End Point To Evaluate Renoprotective Drug Effects?Impact of safety-related regulatory action on drug use in ambulatory care in the Netherlands.The ISoP CommSIG for Improving Medicinal Product Risk Communication: A New Special Interest Group of the International Society of Pharmacovigilance.The RIMES Statement: A Checklist to Assess the Quality of Studies Evaluating Risk Minimization Programs for Medicinal Products.Communication in drug safety: a report from an interactive debate held at the 10th annual meeting of the international society of pharmacovigilance (ISoP), 2010.Healthcare professionals' self-reported experiences and preferences related to direct healthcare professional communications: a survey conducted in the Netherlands.Safety Communication Tools and Healthcare Professionals' Awareness of Specific Drug Safety Issues in Europe: A Survey Study.Interest in a Mobile App for Two-Way Risk Communication: A Survey Study Among European Healthcare Professionals and Patients.Precision medicine in diabetes and diabetic kidney disease: Regulatory considerationsDevelopment and Initial Validation of a Patient-Reported Adverse Drug Event QuestionnaireHealthcare professionals' level of medication knowledge in Africa: a systematic reviewEffect of safety issues with HIV drugs on the approval process of other drugs in the same class: an analysis of European Public Assessment ReportsGFR decline as an end point for clinical trials in CKD: a view from EuropeWhen direct health-care professional communications have an impact on inappropriate and unsafe use of medicinesCritically reviewing impact of regulatory actions, not just FDA's
P50
Q30407219-0C6479D1-51D9-44C3-9E59-9A0A5632CD3DQ30844578-85CD97AA-D6E8-416B-A076-3F85FE7E5B8BQ34407111-E306DCE0-8F80-48AE-B24E-F2C9F7D27068Q34555590-6CAFA38F-FC02-4D4A-A55B-1EFEB69EA5E4Q35684826-F0056334-3001-42F1-AB71-D44B9B8FDEF0Q36185721-DBAE281A-9F08-4618-BEEE-A7AA2D94F496Q37768277-65215520-DC53-4267-A566-D54ED233A2D0Q37777390-958C5D67-65CC-4B86-825A-97C98840022DQ37943437-1A31FAFB-E64E-45D2-8BD1-568C52DADFDFQ38000336-71279791-57B0-4EF9-ACFE-A46D218CBF04Q38504869-5CBE179B-E984-4354-84A2-56E0313CC6D9Q38528288-4D3255D0-8FDF-4EA1-8B4B-E15D5E3F3CEFQ38579811-74393F35-260B-42A6-9919-65F0BF824CDBQ38604442-A98A259F-95A4-4ED3-9620-3DB5179C3BDEQ38765887-409AF545-B183-4A87-A6EC-FDEEB0A0E12EQ38905424-9DC64012-307C-47DF-9FB6-04521A4EDD9CQ39871580-B58BF0EF-4319-4C5D-9193-C54ED09E767DQ40095373-18C6E01D-A6BB-48EC-8F54-63DDDFA91DE8Q40356226-174A12ED-0CDB-4316-B9D1-1F67E504E94CQ42136623-52988067-FC4D-4793-9E11-0BFFA829B1D1Q43891080-225CB7D7-433F-4CA6-9451-E89830AA5053Q44703306-1F1D3190-3505-4852-A21A-B066BA1F2513Q45022481-AAA54CE1-E3BF-4CD2-99A5-0E9DA647853BQ46813889-F4D48EBA-2AA8-49F7-8B74-E6D75D267C12Q47102430-4C588CF4-86F3-458C-B679-46E4EA7F0E43Q47942386-2835E718-9ADF-45BE-8D7C-14847C2DF221Q47947189-E6AB4FA6-9E72-418A-B66F-BB14081C9F4AQ49045547-71039FEA-6CFD-4E14-9C2D-D3703CA3BC17Q50016764-ECC0B5A7-1B45-4F23-B158-7BF199F70E89Q51169048-8E43D7AC-5E5A-4625-8D7F-64A10F9E29BDQ51310674-3C936B59-473F-451E-8A4E-2DDBDF2F6163Q52676212-AFFC7C57-6E9C-41DD-948E-41DD688C0FD3Q55251571-291C21B1-A29C-4AE8-AF40-ECAC6E5AD028Q57189955-4528FC76-BDF9-4716-8ED2-6856C06FB08FQ59299160-7267187F-4B0D-4D34-97E1-EE7F872A97D9Q61592827-2B6090D7-022F-47A3-AA27-028B3E59D6F4Q85058696-5DD1477F-94F8-477D-84C7-F98BB916136AQ86125352-C91A4DA7-2C26-4F7A-A922-531F379684B1Q86207642-2C88AF05-426C-4F89-9A27-1BD01ACC1D5BQ87044443-320189FB-7E90-43A4-8D29-9FE75DA50067
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Peter Mol
@ast
Peter Mol
@en
Peter Mol
@es
Peter Mol
@nl
type
label
Peter Mol
@ast
Peter Mol
@en
Peter Mol
@es
Peter Mol
@nl
prefLabel
Peter Mol
@ast
Peter Mol
@en
Peter Mol
@es
Peter Mol
@nl
P106
P1153
8503767200
P31
P496
0000-0002-4262-3180